Clinical and histologic signs of regression two months after initiation of treatment with dabrafenib and trametinib in a case of stage IIIc BRAF V600E-positive scalp melanoma

被引：0
|
作者：
Wei, Erin [1 ]
Cordero, Roberto Ruiz [2 ]
Zhou, Xiaolong [1 ]
Feun, Lynn [3 ]
Thomas, Giovanna [4 ]
Cho-Vega, Jeong Hee [2 ]
机构：
[1] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Dept Pathol, Dermatopathol, Miami, FL 33136 USA
[3] Univ Miami, Miller Sch Med, Dept Med Hematol Oncol, Miami, FL 33136 USA
[4] Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2015年 / 72卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
269
引用
收藏
页码：AB165 / AB165
页数：1
相关论文
共 41 条
  • [31] Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma
    Weber, J. S.
    Haque, W.
    Markovic, S. N.
    Salama, A. K. S.
    Mehmi, I.
    Sullivan, R. J.
    Najjar, Y. G.
    van Akkooi, A. C. J.
    Menzies, A. M.
    Long, G. V.
    Taylor, A. M.
    Haanen, J. B. A. G.
    Zijlker, L.
    Davis, K.
    Karanth, S.
    Shah, R.
    Connolly, L.
    Norton, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S657 - S658
  • [32] Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
    Weng, C.
    Tang, K.
    Jin, S.
    Zhou, C.
    Yao, Y.
    Su, J-W.
    Chen, H.
    Liu, K.
    Li, Y.
    Yang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1688 - S1688
  • [33] A Case of Liver Injury Immediately After Initiation of Triple Therapy in a Patient With BRAF V600E Mutation-Positive Colorectal Cancer
    Aimono, Yuka
    Ohkawara, Atsushi
    Ogawa, Tatsunori
    Yagisawa, Takahiro
    Tamura, Akihiro
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [34] Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
    Li, Dan
    Liu, Jiayin
    Zhang, Xue
    Han, Jing
    Jin, Hui
    Wang, Long
    Feng, Li
    Fan, Zhisong
    Zuo, Jing
    Wang, Yudong
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3175 - 3179
  • [35] Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report
    Inoue, Takako
    Kunimasa, Kei
    Tamiya, Motohiro
    Kawamura, Takahisa
    Minami, Toshiyuki
    Nishino, Kazumi
    THORACIC CANCER, 2024, 15 (11) : 929 - 933
  • [36] Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
    Long, Georgina V.
    Stroyakovskiy, Daniil
    Gogas, Helen
    Levchenko, Evgeny
    De Braud, Filippo G.
    Larkin, James M. G.
    Garbe, Claus
    Jouary, Thomas
    Hauschild, Axel
    Grob, Jean Jacques
    Chiarion-Sileni, Vanna
    Lebbe, Celeste
    Mandala, Mario
    Millward, Michael
    DeMarini, Douglas James
    Irani, Jhangir G.
    Jin, Fan
    Swann, R. Suzanne
    Mookerjee, Bijoyesh
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after de fi nitive surgery: a multicenter, retrospective cohort study (vol 65, 102290, 2023)
    Bai, Xue
    Shaheen, Ahmed
    Grieco, Charlotte
    Arienzo, Paolo D.
    Mina, Florentia
    Czapla, Juliane A.
    Lawless, Aleigha R.
    Bongiovanni, Eleonora
    Santaniello, Umberto
    Zappi, Helena
    Dulak, Dominika
    Williamson, Andrew
    Lee, Rebecca
    Gupta, Avinash
    Li, Caili
    Si, Lu
    Ubaldi, Martina
    Yamazaki, Naoya
    Ogata, Dai
    Johnson, Rebecca
    Park, Benjamin C.
    Jung, Seungyeon
    Madonna, Gabriele
    Hochherz, Juliane
    Umeda, Yoshiyasu
    Nakamura, Yasuhiro
    Gebhardt, Christoffer
    Festino, Lucia
    Capone, Mariaelena
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Lo, Serigne N.
    V. Long, Georgina
    Menzies, Alexander M.
    Namikawa, Kenjiro
    Mandala, Mario
    Guo, Jun
    Lorigan, Paul
    Najjar, Yana G.
    Haydon, Andrew
    Quaglino, Pietro
    Boland, Genevieve M.
    Sullivan, Ryan J.
    Furness, Andrew J. S.
    Plummer, Ruth
    Flaherty, Keith T.
    ECLINICALMEDICINE, 2024, 71
  • [38] Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus
    Del Vecchio, M.
    Atkinson, V. G.
    Ryll, B.
    Menzies, A. M.
    Aubin, F.
    Sileni, V. Chiarion
    Ferraresi, V.
    Lesimple, T.
    Rinaldi, G.
    Saiag, P.
    Robert, C.
    Dutriaux, C.
    Gogas, H. J.
    Demidov, L.
    Gupta, A.
    Banerjee, H.
    Sudhir, S.
    Miranda, F.
    Lau, M. R.
    Grob, J. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S914 - S914
  • [39] Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
    Robert, C.
    Karaszewska, B.
    Schachter, J.
    Rutkowski, P.
    Mackiewicz, A.
    Stroyakovskiy, D.
    Lichinitser, M.
    Dummer, R.
    Grange, F.
    Mortier, L.
    Chiarion-Sileni, V.
    Drucis, K.
    Krajsova, I.
    Hauschild, A.
    Mookerjee, B.
    Legos, J.
    Schadendorf, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S664
  • [40] Case Report: Rapid Regression of disseminated Brain Filiae of malignant Melanoma after single PD1 Antibody Pembrolizumab plus six Weeks of targeted Therapy with Encorafenib and Binimetinib after prior Relapse/Progress with Vemurafenib and Cobimetinib under seven Months Treatment for BRAF V600E Mutation
    Bender, A.
    Geschnell, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 33 - 34
12345